Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Total Non-Current Liabilities (2016 - 2025)

Ligand Pharmaceuticals' Total Non-Current Liabilities history spans 16 years, with the latest figure at $506.7 million for Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities rose 504.54% year-over-year to $506.7 million; the TTM value through Sep 2025 reached $506.7 million, up 504.54%, while the annual FY2024 figure was $81.2 million, 38.65% up from the prior year.
  • Total Non-Current Liabilities for Q3 2025 was $506.7 million at Ligand Pharmaceuticals, up from $106.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $520.6 million in Q1 2021 and bottomed at $57.7 million in Q3 2023.
  • The 5-year median for Total Non-Current Liabilities is $137.4 million (2022), against an average of $214.5 million.
  • The largest annual shift saw Total Non-Current Liabilities crashed 72.85% in 2023 before it soared 504.54% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $446.9 million in 2021, then crashed by 69.25% to $137.4 million in 2022, then tumbled by 57.4% to $58.5 million in 2023, then surged by 38.65% to $81.2 million in 2024, then soared by 524.22% to $506.7 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Total Non-Current Liabilities are $506.7 million (Q3 2025), $106.9 million (Q2 2025), and $95.7 million (Q1 2025).